Last reviewed · How we verify
Pre-ERCP rectal Indomethacin
At a glance
| Generic name | Pre-ERCP rectal Indomethacin |
|---|---|
| Sponsor | Air Force Military Medical University, China |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Indian National Study to Assess Incidence and Severity of Post-ERCP Pancreatitis After Following SOP
- Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis (PHASE3)
- Rectal NSAIDs With/Without PD Stent for PEP Prevention (NA)
- Indomethacin vs Diclofenac for Preventing PEP (NA)
- Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis (PHASE4)
- Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis (PHASE3)
- Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac (NA)
- Prospective Comparison Between Ultra Early NKF Versus Standard Cannulation Alone (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |